Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Antibody Therapeutics
|
June 16, 2023
Current status of drug development for patients with multiple myeloma: a review of comparison in China and the rest of world
Lei Huang, Jingyu Zhang, Elizabeth Punnoose, et al.
Frontiers in Oncology
|
August 29, 2022
Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling
Jin Wang, Yi Hu, Habib Hamidi, et al.
Leukemia & Lymphoma
|
March 24, 2015
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
Thomas J Kipps, Herbert Eradat, Sebastian Grosicki, et al.
Clinical Pharmacology and Therapeutics
|
April 18, 2025
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes
Jiawen Zhu, Amy Schroeder, Sabine Frank, et al.
The Journal of Molecular Diagnostics : JMD
|
April 6, 2020
Genomic Analysis of Circulating Tumor Cells at the Single-Cell Level
Shan Lu, Chia-Jung Chang, Yinghui Guan, et al.
Leukemia & Lymphoma
|
December 16, 2020
Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma
Edith Szafer-Glusman, Juan Liu, Arijit Sinha, et al.
American Journal of Hematology
|
March 2, 2017
BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab
Sarah Huet, Edith Szafer-Glusman, Bruno Tesson, et al.
Oncotarget
|
February 18, 2017
Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients
Marius Ilie, Edith Szafer-Glusman, Véronique Hofman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2009
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models
Klaus P Hoeflich, Carol O'Brien, Zachary Boyd, et al.
Ebiomedicine
|
June 25, 2018
Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies
Peng-Peng Xu, Chun Sun, Xu Cao, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Antibody Therapeutics
|
June 16, 2023
Current status of drug development for patients with multiple myeloma: a review of comparison in China and the rest of world
Lei Huang, Jingyu Zhang, Elizabeth Punnoose, et al.
Frontiers in Oncology
|
August 29, 2022
Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling
Jin Wang, Yi Hu, Habib Hamidi, et al.
Leukemia & Lymphoma
|
March 24, 2015
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
Thomas J Kipps, Herbert Eradat, Sebastian Grosicki, et al.
Clinical Pharmacology and Therapeutics
|
April 18, 2025
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes
Jiawen Zhu, Amy Schroeder, Sabine Frank, et al.
The Journal of Molecular Diagnostics : JMD
|
April 6, 2020
Genomic Analysis of Circulating Tumor Cells at the Single-Cell Level
Shan Lu, Chia-Jung Chang, Yinghui Guan, et al.
Leukemia & Lymphoma
|
December 16, 2020
Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma
Edith Szafer-Glusman, Juan Liu, Arijit Sinha, et al.
American Journal of Hematology
|
March 2, 2017
BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab
Sarah Huet, Edith Szafer-Glusman, Bruno Tesson, et al.
Oncotarget
|
February 18, 2017
Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients
Marius Ilie, Edith Szafer-Glusman, Véronique Hofman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2009
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models
Klaus P Hoeflich, Carol O'Brien, Zachary Boyd, et al.
Ebiomedicine
|
June 25, 2018
Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies
Peng-Peng Xu, Chun Sun, Xu Cao, et al.
Page
of 2